Citation Impact
Citing Papers
Vaccine-delivered HIV envelope inhibits CD4+ T-cell activation, a mechanism for poor HIV vaccine responses
2006 StandoutNobel
CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract
2004 Standout
Memory CD8 + T Cells Are Required for Protection from Persistent Hepatitis C Virus Infection
2003 StandoutNobel
Sustained Conservation of CD4 + T Cells in Multiprotein Triple Modality-Immunized Rhesus Macaques after Intrarectal Challenge with Simian Immunodeficiency Virus
2006
Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study
1999
Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA
2007
Duration of antiviral immunity after smallpox vaccination
2003 Standout
Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies
2007 StandoutNobel
Sialic Acid 9-O-Acetylation on Murine Erythroleukemia Cells Affects Complement Activation, Binding to I-type Lectins, and Tissue Homing
1996
Bitter taste, phytonutrients, and the consumer: a review
2000 Standout
Structural and functional analysis of orthopoxvirus epitopes with neutralizing monoclonal antibodies
1990
Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine
2001 StandoutScience
Coronavirus envelope protein: current knowledge
2019 Standout
Prospects for a vaccine against the hepatitis C virus
2005 StandoutNatureNobel
Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model
2018
Regulatory T cells, tumour immunity and immunotherapy
2006 Standout
Immunogenicity of an inactivated hepatitis A vaccine administered according to two different schedules and the interference of other “travellers” vaccines with the immune response
1996
Nasopharyngeal carcinoma
2015 Standout
Clinical Experience With An Inactivated Hepatitis A Vaccine
1995
The chemical diversity and distribution of glucosinolates and isothiocyanates among plants
2001 Standout
Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin
2005
The complete DNA sequence of vaccinia virus
1990 Standout
Epstein–Barr virus: 40 years on
2004 Standout
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
2002
Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization
2017 StandoutNobel
Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate
2007
Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors
2004
New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview
1999
Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins
2004
Biosynthesis of glucosinolates – gene discovery and beyond
2010 Standout
Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein
2001 StandoutNobel
Diversity in the sialic acids
1992
Generation of a reporter yellow fever virus for high throughput antiviral assays
2020 StandoutNobel
Design of therapeutic vaccines: hepatitis B as an example
2011
Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
1998
Variation of glucosinolate accumulation among different organs and developmental stages of Arabidopsis thaliana
2003 Standout
High-pressure liquid chromatography of sialic acids on a pellicular resin anion-exchange column with pulsed amperometric detection: A comparison with six other systems
1990
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
Vaccinia virus host range genes
1990
Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway
2021 StandoutNobel
Exploitation of natural products as an alternative strategy to control postharvest fungal rotting of fruit and vegetables
2004 Standout
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
2011 StandoutNobel
Simian Immunodeficiency Virus SIVagm.sab Infection of Caribbean African Green Monkeys: a New Model for the Study of SIV Pathogenesis in Natural Hosts
2006 StandoutNobel
Sexually Transmitted Infections Treatment Guidelines, 2021
2021 Standout
„Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype
1975 Standout
CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model
2003
The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC in Rhesus Monkeys
2013
Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara
1996
Antimicrobial activity of vascular plants
1959
Anti-reproductive and other medicinal effects of Tropaeolum tuberos um
1982
Poxviruses: Interfering with Interferon
1998
Recombinant modified vaccinia virus Ankara–simian immunodeficiency virusgag polelicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
1998
Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 + Lymphocytes
1999 StandoutScience
Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster
2012 StandoutNobel
HL-A 3,7 AND LYMPHOCYTE CYTOTOXIC ACTIVITY
1974
Liposomal Formulations in Clinical Use: An Updated Review
2017 Standout
Vaccinia Virus Inhibits the Maturation of Human Dendritic Cells: A Novel Mechanism of Immune Evasion
1999 StandoutNobel
High Levels of Viral Replication during Primary Simian Immunodeficiency Virus SIVagm Infection Are Rapidly and Strongly Controlled in African Green Monkeys
2000 StandoutNobel
Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures
2007 Standout
Antiviral Actions of Interferons
2001 Standout
Mucosal Priming of Simian Immunodeficiency Virus-Specific Cytotoxic T-Lymphocyte Responses in Rhesus Macaques by theSalmonellaType III Secretion Antigen Delivery System
2003
IMMUNOLOGY OF MULTIPLE SCLEROSIS
2005 Standout
Atraumatic Oral Spray Immunization with Replication-Deficient Viral Vector Vaccines
2007 StandoutNobel
Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
1999 Standout
Biological and Phytochemical Screening of Plants
1966 Standout
METABOLIC SUBSTRATE ENGINEERING AS A TOOL FOR GLYCOBIOLOGY
2002 StandoutNobel
Natural ligands of the B cell adhesion molecule CD22 beta can be masked by 9-O-acetylation of sialic acids.
1994
Preformed Antimicrobial Compounds and Plant Defense against Fungal Attack.
1996 Standout
Yellow fever 17D as a vaccine vector for microbial CTL epitopes
2005 StandoutNobel
Cloning and expression of foreign genes in vaccinia virus, using a host range selection system
1989
Dual Stimulation of Epstein-Barr Virus (EBV)-Specific CD4+- and CD8+-T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal Carcinoma
2003
Strategies for Cancer Vaccine Development
2010
High Levels of Viral Replication Contrast with Only Transient Changes in CD4+and CD8+Cell Numbers during the Early Phase of Experimental Infection with Simian Immunodeficiency Virus SIVmnd-1 inMandrillus sphinx
2002 StandoutNobel
Comparative Efficacy of Recombinant Modified Vaccinia Virus Ankara Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol and/or Env in Macaques Challenged with Pathogenic SIV
2000
HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response
2000 StandoutNobel
Identification of Poxvirus Genome Uncoating and DNA Replication Factors with Mutually Redundant Roles
2018
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses
2008 StandoutNobel
Induction of Protective Immunity against Malaria by Priming-Boosting Immunization with Recombinant Cold-Adapted Influenza and Modified Vaccinia Ankara Viruses Expressing a CD8+-T-Cell Epitope Derived from the Circumsporozoite Protein ofPlasmodium yoelii
2003
Inactivation of CMP- N -acetylneuraminic acid hydroxylase occurred prior to brain expansion during human evolution
2002 StandoutNobel
Glucosinolates and their breakdown products in food and food plants
1983 Standout
Ecology of Infochemical Use by Natural Enemies in a Tritrophic Context
1992 Standout
Cell-Mediated Immune Responses in Tuberculosis
2009 Standout
Simian Immunodeficiency Virus Replicates to High Levels in Sooty Mangabeys without Inducing Disease
1998 StandoutNobel
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
1996
C7L Family of Poxvirus Host Range Genes Inhibits Antiviral Activities Induced by Type I Interferons and Interferon Regulatory Factor 1
2012 StandoutNobel
Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guerin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara
2003
Works of H Stickl being referenced
An Antibiotically Active Plant Substance.
1954
MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA).
1974
Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine
1992
Veränderung der Acylneuraminsäuregehalte auf T-Lymphozyten und im Plasma bei Erkrankung an Mamma-Karzinom
1991
Alterations of acyl-neuraminic acids on T-lymphocytes in cases of melanoma
1988
Hepatitis A vaccination: Schedule for accelerated immunization
1992
[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)].
1978
Über den antimikrobisch wirkenden Stoff der Kapuzinerkresse(Tropaeolum maius)
1956
Antibody-dependent lymphocyte cytotoxicity against basic protein of myelin in multiple sclerosis
1980
[An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola (author's transl)].
1975
Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA
1975
MVA-Stufenimpfung gegen Pocken
1974
Smallpox vaccination and its consequences: First experiences with the highly attenuated smallpox vaccine “MVA”
1974
[Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus ("MVA virus")].
1971
Über eine antibiotisch wirksame Pflanzensubstanz1
1954
Lymphocytentransformation bei Multipler Sklerose: Untersuchungen mit Liquor cerebrospinalis, Immunglobulinen und encephalitogenem Protein
1968